Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy.

Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol. 2010 Jun; 202(6):608.e1-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.